- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPYGLASS PHARMA Aktie jetzt für 0€ handeln | |||||
| 10.03. | H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating | 5 | Investing.com | ||
| 09.03. | SpyGlass Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.03. | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 367 | GlobeNewswire (Europe) | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| 03.03. | Leerink initiates SpyGlass Pharma stock with Outperform rating | 1 | Investing.com | ||
| 03.03. | Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential | 1 | Investing.com | ||
| 09.02. | SpyGlass Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.02. | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | 206 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the closing of its initial public... ► Artikel lesen | |
| 06.02. | SpyGlass Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.02. | SpyGlass Pharma surges on public debut; AgomAb falls | 4 | Seeking Alpha | ||
| 06.02. | Chronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint, raising $150 million | 2 | Renaissance Capital | ||
| 06.02. | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | 1 | FierceBiotech | ||
| 06.02. | SpyGlass Pharma raises $150 million in IPO priced at $16 per share | 1 | Investing.com | ||
| 06.02. | SpyGlass Pharma Prices IPO At $16 Per Share | 693 | AFX News | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| 06.02. | Agomab, SpyGlass Pharma bank a combined $350M in biotech IPOs | 1 | BioPharma Dive | ||
| 06.02. | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Pricing of Initial Public Offering | 174 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the pricing of its initial public... ► Artikel lesen | |
| 05.02. | SpyGlass Pharma, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 29.01. | Chronic eye condition biotech SpyGlass Pharma sets terms for $150 million IPO | 3 | Renaissance Capital | ||
| 29.01. | SpyGlass Pharma, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 20.01. | Agomab and Spyglass Pharma push the IPO button | 2 | pharmaphorum | ||
| 19.01. | Immunology biotech Agomab, eye-focused SpyGlass Pharma are latest biotechs to share IPO ambitions | 1 | FierceBiotech |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,69 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -5,18 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results |
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | +0,54 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | -5,89 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | +0,96 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| LENZ THERAPEUTICS | 10,480 | -8,79 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 7,940 | -7,08 % | Kyverna Therapeutics: Ein kommender Biotech-Star? | Die Aktie von Kyverna Therapeutics rückt zunehmend in den Blick von Investoren, die auf bahnbrechende CAR-T-Therapien im Autoimmunbereich setzen. Mit vielversprechenden Studiendaten und einer bevorstehenden... ► Artikel lesen | |
| NUVALENT | 94,82 | -2,31 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,325 | -4,63 % | ADMA Biologics Announces $200 Mln Capital Return Plan |
Das Unternehmen SPYGLASS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 26,000 Euro und damit +1,13 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYGLASS PHARMA INC finden Sie auf Wallstreet Online.